Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "cardiotoxicity" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 28
Tytuł:
Complete response to pixantrone as a salvage therapy in a relapsed/refractory diffuse large B-cell lymphoma
Autorzy:
Pasternak, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1035645.pdf
Data publikacji:
2020
Wydawca:
Medical Education
Tematy:
DLBCL lymphoma
cardiotoxicity
pixantrone
Opis:
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). It is one of the most common form of the disease. A combination of chemotherapy with anthracycline and a monoclonal antibody targeting CD20 is used as a I line therapy. About two out of three people with DLBCL achieve and maintain complete remission after this treatment. In case of relapse or refractory disease a salvage high‑dose chemotherapy followed by autologous stem cell transplantation (HD-ASCT) is the standard of care. Patientrs who relapse after HD-ASCT have a very poor prognosis. Pixantrone is a new anthracycline derivative registered to treat relapsed/refractory DLBCL in adult patients. It is a cytostatic agent with a reduced cardiotoxicity comparing to classic anthracyclines. Herein, we report two cases of relapsed/refractory DLBCL treated with pixantrone as a salvage therapy. The first case concernes a 58-year-old female patient with a diagnose of DLBCL, who relapsed after four prior lines of therapy (R-CHOP, ICE, HD-Mtx, CSN radiation) and achieved complete remission after pixantrone therapy, but died of acute myeloid leukemia 3 months after the end of treatment. Second case is a story of a 75-year-old female patient treated with two prior lines of treatment (R-CHOP, R-IVE), who achieved complete remission after a III line of therapy with pixantrone. Pixantrone monotherapy proves to be effective in relapsed/refractory DLBCL. This treatment is well tolerated in a group of elderly patients and can be also used in a group of patients with a limited cardiac function.
Źródło:
OncoReview; 2020, 10, 2; 62-68
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiotoxicity in breast cancer patients after radiotherapy – modern methods of minimizing the dose to the heart and dilemmas of choosing critical cardiac structures for monitoring dose distribution
Autorzy:
Pudełek, Katarzyna
Pudełek, Jacek
Nawrocki, Sergiusz
Powiązania:
https://bibliotekanauki.pl/articles/1064839.pdf
Data publikacji:
2016
Wydawca:
Medical Education
Tematy:
breast cancer
cardiotoxicity
radiotherapy
Opis:
Radiotherapy in breast cancer patients is an important component of multidisciplinary treatment. It reduces the risk of local recurrence and mortality from breast cancer. However, it can lead to secondary effects due to the presence of the heart within the irradiation field. Adjuvant radiation therapy for breast cancer increases the risk of coronary artery disease, myocardial infarction and cardiovascular death. It is important to determine the optimal treatment to minimize cardiotoxicity. Modern radiotherapy techniques may reduce radiation-induced cardiac toxicity, but it is necessary to determine the most sensitive structures within the heart, tolerance doses, and methods for early detection and monitoring of adverse effects.
Źródło:
OncoReview; 2016, 6, 3; A113-117
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardiac amyloidosis: a hidden cause of cardiovascular complications in oncology practice
Autorzy:
Mladosievicova, Beata
Poljak, Zuzana
El-Hassoun, Olja
Roziakova, Lubica
Carter, Andrea
Powiązania:
https://bibliotekanauki.pl/articles/1065345.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
amyloidosis
cancer
cardiotoxicity
transthyretin
Opis:
Amyloidosis is rare, but known cause of heart failure, cardiomyopathy, coronary artery disease, disorders of cardiac conduction system and valvular damage. Disease often remains undetected until it reaches an advanced stage. Currently, we distinguish several types of amyloidosis. Cardiac amyloidosis may be caused by cancer, chronic inflammation, genetic factors and by aging related processes. Overproduction of amyloidogenic proteins by tumor cells has a key role in the pathogenesis of immunoglobulin light chain amyloidosis. Cardiovascular complications in patients with amyloidosis can be induced by insoluble deposits of misfolded proteins or by direct toxic effects of amyloidogenic molecules on cardiomyocytes and endothelial cells. In this review we focus mainly on pathophysiological mechanisms of cardiac amyloidosis, classification of cardiac amyloidosis types and their cardiovascular manifestations.
Źródło:
OncoReview; 2014, 4, 4; A137-A143
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
QUERCETIN ATTENUATES OXIDATIVE STRESS, INFLAMMATION AND CARDIAC DYSFUNCTION IN ACRYLAMIDE- INDUCED CARDIOTOXICITY
Autorzy:
Kushwah, Ajay S.
KALIA, TARANBIR S.
Powiązania:
https://bibliotekanauki.pl/articles/895356.pdf
Data publikacji:
2020-04-29
Wydawca:
Polskie Towarzystwo Farmaceutyczne
Tematy:
cardiotoxicity
acrylamide
quercetin
myocardial damage
Opis:
Acrylamide (ACR) is a foodborne toxic agent, formed in food when processed at high temperature. This study aimed at evaluating the biochemical changes induced by ACR and the effect of Quercetin as a treatment against ACR induced cardiotoxicity in rats. Wistar rats of either sex (n=6) were divided into four groups as follows: normal control, an Acrylamide control group, Quercetin groups (25 and 50 mg/kg). Diagnostics characteristics were assessed daily, at the end of the study (4 weeks) evaluate hemodynamic parameters, the blood sample was collect for estimation of biochemical and rats were decapitated excised hearts, cleaned and weighed. Heart homogenate was used to determine antioxidants and oxidative levels, and histopathological evaluations were carried out to determine changes induced by Acrylamide. As compared control groups, ACR treated rats show altered significantly (P < 0.05) general characteristic and also elevated myocardial damage markers, altered hemodynamic, oxidative stress level, increased expression of inflammatory cytokines and induced histopathological changes. Treatment with Quercetin at 25 mg/kg and 50 mg/kg recouped the above changes significantly (P < 0.05), 50 mg/kg being more prominent. The present study has concluded that Quercetin protects against Acrylamide-induced cardiotoxicity.
Źródło:
Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 2; 343-352
0001-6837
2353-5288
Pojawia się w:
Acta Poloniae Pharmaceutica - Drug Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Efficacy and safety of liposomal doxorubicin in a patient treated for metastatic breast cancer
Autorzy:
Streb, Joanna
Słowik, Agnieszka
Powiązania:
https://bibliotekanauki.pl/articles/1065206.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
breast cancer
cardiotoxicity
liposomal doxorubicin
Opis:
Liposomal doxorubicin is a newer form of chemotherapeutic agents that, due to its own special properties, preferably accumulates in cancer tissue. On the other hand, it shows lower affinity to cardiomyocytes and in this way is less cardiotoxic. As a result of that, there is the possibility to use liposomal form of doxorubicin until disease progression or chemotherapy intolerance in palliative setting, without treatment cessation after reaching the maximum cumulative dose of conventional doxorubicin. In this article we describe the case of a female patient diagnosed with breast cancer who was primary treated with adjuvant treatment, including chemotherapy and in whom a disease recurrence occurred after seven years of observation. As a primary palliative treatment the patient received chemotherapy based on liposomal doxorubicin and cyclofosphamide with a very good tolerance. The initial response was partial remission in lungs and in mediastinal lymph nodes. During the whole course of therapy there were no pathological changes in electrocardiogram, no signs and no symptoms of congestive heart failure, and the left ventricular ejection fraction was within normal limits.
Źródło:
OncoReview; 2015, 5, 2; A67-70
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Imaging techniques used to detect oncological treatment complications
Autorzy:
Sosnowska-Pasiarska, Barbara
Góźdź, Stanisław
Powiązania:
https://bibliotekanauki.pl/articles/773575.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
cardiac imaging techniques
cardiotoxicity
echocardiography
Opis:
Oncological drugs are toxic for the cardiovascular system, directly affecting cardiac function and anatomy. Oncological treatment complications may thus take the form of asymptomatic myocardial dysfunction, overt heart failure, exacerbation of the symptoms of ischaemic heart disease, thromboembolic complications, arterial and pulmonary hypertension, pericardial complications, valvular disease and arrhythmia. Presently, we have a number of diagnostic tools at our disposal to detect cardiotoxicity, and the choice of one imaging technique over the others depends on the availability of that particular diagnostic method, and on its ability to provide optimum visualization. The basic method for cardiac assessment in oncological patients is transthoracic echocardiography (TTE). It is a widely available method which enables assessment of cardiac structures and haemodynamics without exposing the patient to an additional dose of ionizing radiation. In the case of poor TTE visualization, a recommended method for the assessment of cardiac function and structures is magnetic resonance. Chest, heart and coronary artery CT is also very useful in the diagnostics of oncological treatment complications. Moreover, cardiotoxicity diagnostics also involves nuclear medicine imaging techniques, including gated radionuclide ventriculography, whose advantage is high repeatability, with the disadvantage being the patient’s exposure to ionizing radiation and limited information on the structure and function of the myocardium. Both ECG-gated single photon emission computed tomography (SPECT) and positron emission tomography (PET) deliver information on the global and regional function of the left ventricle, presence of intraventricular synchrony, and myocardial perfusion. Early detection of subclinical dysfunction of the left ventricular myocardium in patients treated with potentially cardiotoxic drugs is well-grounded and aimed at the prevention of cardiovascular mortality by means of a primary prevention strategy.
Źródło:
OncoReview; 2017, 7, 2; 57-63
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The oncological treatment and cardiotoxicity problem - the role of biomarkers
Autorzy:
Dudek, Magdalena
Kałużna-Oleksy, Marta
Migaj, Jacek
Lesiak, Maciej
Straburzyńska-Migaj, Ewa
Powiązania:
https://bibliotekanauki.pl/articles/2032982.pdf
Data publikacji:
2020-12-02
Wydawca:
Medical Education
Tematy:
cardiotoxicity
biomarkers
cardiooncology
ST2
troponin
Opis:
Cancer and cardiovascular diseases are a leading causes of morbidity and mortality in developed countries. Cardiological complications of oncological treatment are a  significant problem that can be manifested in both permanent and transient cardiac dysfunction including myocardial damage, left ventricular dysfunction, and heart failure, hypertension, ischemia, as well as arrhythmias or QT prolongation, which can be life-threatening. Early detection of cardiotoxicity due to cancer treatment is crucial in the prevention of adverse cardiovascular outcomes in this group of patients. In this review we try to summarize the role of biomarkers in the detection of cardiotoxicity due to cancer treatment.
Źródło:
OncoReview; 2020, 10, 4; 130-133
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Pixantrone – anticancer drug in the monotherapy of aggressive lymphomas
Autorzy:
Hałka, Janusz
Powiązania:
https://bibliotekanauki.pl/articles/1035635.pdf
Data publikacji:
2020-06-30
Wydawca:
Medical Education
Tematy:
aggressive non-Hodgkin lymphoma
cardiotoxicity
pixantrone
Opis:
Pixantrone is a first drug aza-anthracenedione approved as monotherapy of relapsed or refractory aggressive lymphomas. This drug has the unique chemical structure and mode of action properties distinguishing it from anthracyclines and anthracenediones. Pixantrone is one of the treatment option for heavily pretreated patients which to receive their living with doxorubicin and the further application from anthracyclines potentially can lead anthracycline-induced congestive heart failure. The benefit of pixantrone treatment has not been established in patients when used as V line or greater chemotherapy in patients who are refractory to last therapy. In general, pixantrone seems to be safe and manageable. In various trials, there were no unexpected side effects reported and no trials were closed prematurely because of side effects. In an evaluation of 12 clinical trials with pixantrone, the most common side effect (all grades) was hematological toxicity, mainly neutropenia (50% of patients; grade third/fourth: 41%), leukopenia (25%), anemia (31%), and thrombocytopenia (21%). Hematological toxicity was the main reason for a delayed start of subsequent cycles or for omitting the day-15 dose of pixantrone. In the outpatient setting, it is worth considering the use of hematopoietic growth factors. Other side effects included asthenia (23%), pyrexia (23%), and nausea, most patients experienced reversible skin discoloration
Źródło:
OncoReview; 2020, 10, 2; 48-51
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity
Autorzy:
Chmielowska, Ewa
Powiązania:
https://bibliotekanauki.pl/articles/1065040.pdf
Data publikacji:
2015
Wydawca:
Medical Education
Tematy:
HER-2 overexpression
cardiotoxicity
liposomal doxorubicin
Opis:
We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 mitral and tricuspid valvular insufficiency as a result of uncontrolled hypertension. In 2013, the patient was diagnosed with luminal B2 breast cancer with liver and bone metastases, and a large infiltration of the left breast together with the surrounding soft tissue. She was treated with liposomal doxorubicin and cyclophosphamide, with the dose of anthracycline slightly reduced to 50 mg/m2 because of the elevated liver enzymes. She was in complete remission during treatment, without any cardiac or hematologic toxicity. The treatment was prolonged to eight cycles until the liver tests returned to normal. The cumulative dose of liposomal doxorubicin amounted to 400 mg/m2 (with the maximum recommended dose of 600 mg/m2). We decided to administer the liposomal form of doxorubicin, which is less cardiotoxic than conventional doxorubicin, as first-line treatment in order to prevent cardiotoxicity in a patient who is a candidate for another cardiotoxic therapy involving trastuzumab in the future. The patient’s disease progressed 10 months following the completion of first-line therapy. There are no cardiologic contraindications to trastuzumab and there are no signs of liposomal doxorubicin-related cardiotoxicity or deterioration of the valvular insufficiency.
Źródło:
OncoReview; 2015, 5, 1; A11-A15
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Myocardial dysfunction related to trastuzumab therapy – is effective treatment always possible?
Autorzy:
Szmit, Sebastian
Kownacki, Łukasz
Torbicki, Adam
Powiązania:
https://bibliotekanauki.pl/articles/1065798.pdf
Data publikacji:
2014
Wydawca:
Medical Education
Tematy:
breast cancer
cardiotoxicity type II
trastuzumab
Opis:
Left ventricle systolic dysfunction manifesting during trastuzumab treatment is defined as cardiotoxicity type II. It is characterized by full reversibility after discontinuation of trastuzumab and cardiological pharmacological treatment. In a group of patients, however, systolic cardiac function does not fully recover. The reasons of this unfavorable prognosis are subject of heated discussion.
Źródło:
OncoReview; 2014, 4, 2; A62-68
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The effect of tilmicosin and diclofenac sodium combination on cardiac biomarkers in sheep
Autorzy:
Yildiz, R.
Durna Corum, D.
Corum, O.
Ider, M.
Atik, O.
Ok, M.
Uney, K.
Powiązania:
https://bibliotekanauki.pl/articles/16647447.pdf
Data publikacji:
2023
Wydawca:
Polska Akademia Nauk. Czasopisma i Monografie PAN
Tematy:
cardiotoxicity
diclofenac
H-FABP
sheep
tilmicosin
Opis:
The aim of this study was to investigate the cardiotoxic effect of the combination of tilmicosin and diclofenac sodium in sheep. Thirty-two sheep were used and were randomly divided into four equal groups as tilmicosin (T), diclofenac sodium (D), tilmicosin+diclofenac sodium (TD) and control (C) group. Group T received a single dose of tilmicosin, Group D was administered diclofenac sodium once a day for 3 days, and group TD was administered diclofenac and tilmicosin at the same doses as group T and D. Group C received NaCl in a similar way. The blood samples were taken before dosing and at 4th, 8th, 24th and 72nd hour post-dosing for measurement of cardiac markers such as H-FABP, cTn-I, CK-MB. H-FABP level of group TD was found to be significantly (p<0.05) higher than of group C at the 8th, 24th and 72nd hour and group D and T at the 72nd hour. cTn-I and CK-MB levels of group TD were found significantly (p<0.05) higher compared with other groups. In conclusion, the combined use of tilmicosin and diclofenac in sheep causes an increase in cardiac biomarkers and it can be stated that this combination of drugs may cause cardiac damage.
Źródło:
Polish Journal of Veterinary Sciences; 2023, 26, 1; 5-12
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Cardio-oncology in Ukraine: experience at Strazhesko Institute of Cardiology
Autorzy:
Kozhukhov, Sergey
Dovganych, Nataliia
Smolanka, Ivan
Lyhyrda, Olga
Powiązania:
https://bibliotekanauki.pl/articles/1035792.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
cardio-oncology
cardiotoxicity
cardiovascular risk factors
Opis:
Anticancer therapies have extended the lives of patients with cancer, but for some, this benefit is tempered by cardiovascular complications. Their number is increasing as a result of an improvement in the early diagnosis of cardiotoxicity caused by chemo- and radiotherapy. Therefore prevention, detection, monitoring, and treatment of cancer patients at risk of cardiotoxicity with or without concomitant CV diseases are very important. Cardio-oncology is a new direction in Ukraine for improving clinical outcomes of cancer patients. This review aims to provide an overview of the rationale for setting up a Cardio-Oncology Unit and reflects our own experience establishing this service.
Źródło:
OncoReview; 2018, 8, 3; 65-69
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Acute myocardial infarction in an elderly patient treated for lung cancer
Autorzy:
Plecka, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/1035799.pdf
Data publikacji:
2018
Wydawca:
Medical Education
Tematy:
carboplatin cardiotoxicity
elderly patients
myocardial infarction
Opis:
There is a growing number of elderly patients, so it is necessary to create new standards of oncologic care for such individuals in order to provide them with the best possible treatment. An elderly woman was treated for locally advanced small-cell lung cancer. Due to the suspicion of coronary disease, arterial hypertension and age, anti-cancer treatment with carboplatin and etoposide was recommended. When carboplatin infusion came to a stop, signs of myocardial infarction in ECG as well as elevated levels of troponin I were reported. Originally, non-invasive treatment was introduced, but several days later three DES stents were placed in coronary arteries. An attempt was made to treat the patient with cisplatin and etoposide, after which respiratory failure, tumor lysis syndrome and pancytopenia occurred. That is why chemotherapy was discontinued at the time. The patient’s tumor area and brain was irradiated. 16 months later, she is still alive without signs of disease progression. New oncologic standards should be elaborated in order to ensure appropriate treatment for elderly patients.
Źródło:
OncoReview; 2018, 8, 3; 76-79
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Limitations in cardiovascular fitness and rehabilitation of oncologically treated patients
Ograniczenia wydolności układu krąŜenia a rehabilitacja pacjentów leczonych onkologicznie
Autorzy:
Hojan, Katarzyna
Powiązania:
https://bibliotekanauki.pl/articles/1963092.pdf
Data publikacji:
2012
Wydawca:
Akademia Wychowania Fizycznego im. Bronisława Czecha w Krakowie
Tematy:
neoplasm
cardiotoxicity
Physical activity
cardio-pulmonary fitness
Opis:
Introduction: Applying increasingly modern forms of cancer treatment contributes to the higher survival of patients with neoplasm. Nevertheless, every single element of such a treatment, no matter how effective, brings some risk of cardiovascular complications.Objective: The study objective was a review of the clinical research analyzing cardiovascular complications resulting from various forms of oncological treatment and the use of rehabilitation in these patients.Material: The study presents contemporary forms of cancer treatment which may cause negative cardiovascular symptoms.Results: Due to their negative influence on the cardiovascular system oncological drugs can be divided into those: causing heart muscle mass loss, arrhythmia, with a cardio depressive effect, hypertension, heart ischemia as well as those enhancing thrombo-embolic disorders. The cardiotoxicity of oncological treatment is very frequent in patients after combination therapy (using chemotherapy or/and radiotherapy) or with coexisting heart disease. According to the heart failure classification every patient after chemotherapy or/and radiotherapy has a higher risk of its development. Thus it is important to know the type of treatment, its dosages, the time from initiation to the treatment completion, so that the rehabilitation program for this group of patients based on exercise is applied through correct medically supervised physical activities.Conclusions: The oncological benefit of therapy is much higher than the possible cardiological risk but, keeping the patient’s wellbeing in mind, an optimal cardiac diagnostic is necessary so as rehabilitation is based on individual cardiac fitness. In patients with cancer, special attention should be paid to the assessment of the cardio-respiratory endurance rates before rehabilitation and the choice of physical activity, sporting discipline made for this group of patients.
Wstęp: Zastosowanie co raz nowszych form terapii w leczeniu onkologicznym poprawia skutecznie przeżycie chorych na nowotwory. Nadal jednak każdy element tej terapii, jakkolwiek bardzo skuteczny, niesie ryzyko powikłań ze strony układu krążenia. Cel: Celem badań było przedstawienie przeglądu badań klinicznych oceniających powikłania w układzie sercowo-naczyniowym wynikające z zastosowania różnych form leczenia onkologicznego oraz rehabilitacji w tej grupie pacjentów. Materiał: W pracy przedstawiono współczesne leczenie nowotworów, które może powodować objawy niepożądane z zakresu układu sercowo-naczyniowego. Wyniki: Leki onkologiczne ze względu na negatywny wpływ na układ sercowo-naczyniowy podzielono na: powodujące utratę masy mięśnia sercowego, wywołujące zaburzenia rytmu i przewodzenia, o działaniu kardiodepresyjnym, powodujące nadciśnienie, niedokrwienie mięśnia sercowego oraz sprzyjające incydentom zakrzepowo-zatorowym. Kardiotoksyczność terapii onkologicznej jest szczególnie wyrażona u pacjentów po leczeniu skojarzonym (z zastosowaniem chemioterapii i radioterapii) lub współistniejącą chorobą serca. Zgodnie z klasyfikacją niewydolności serca kaŜdy pacjent po chemioterapii i/lub radioterapii ma zwiększone ryzyko jej rozwoju, dlatego ważna jest znajomość rodzaju stosowanego leczenia onkologicznego, jego dawek, cykli i czasu od rozpoczęcia lub zakończenia leczenia, aby program usprawniania dla tej grupy pacjentów, oparty o zastosowanie wysiłku fizycznego, był realizowany poprzez właściwą aktywność fizyczną i pod kontrolą lekarza. Wnioski: Korzyść onkologiczna terapii jest dużo wyższa niż potencjalne ryzyko kardiologiczne, ale mając na uwadze dobro pacjenta, konieczna jest optymalna diagnostyka kardiologiczna i prowadzenie rehabilitacji w zależności od określonej wydolności krążenia. U chorych leczonych onkologicznie należy ze szczególną uwagą ocenić wydolność krążeniowo-oddechową przed rozpoczęciem rehabilitacji oraz zaproponowaniem aktywności fizycznej (np. dyscypliny sportowej) w tej grupie pacjentów.
Źródło:
Medical Rehabilitation; 2012, 16(1); 19-25
1427-9622
1896-3250
Pojawia się w:
Medical Rehabilitation
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Ocena kardiotoksyczności u pacjentek z rakiem piersi leczonych trastuzumabem*
Evaluation of cardiotoxicity in trastuzumab-treated women with breast cancer
Autorzy:
Sidło-Stawowy, Agata
Sawicka, Magdalena
Kubeczko, Marcin
Sikoń, Ewelina
Piszko, Justyna
Maruszczyk, Wojciech
Stando, Rafał
Bracik, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1038053.pdf
Data publikacji:
2013
Wydawca:
Śląski Uniwersytet Medyczny w Katowicach
Tematy:
kardiotoksyczność
rak piersi
trastuzumab
cardiotoxicity
breast cancer
Opis:
INTRODUCTION Breast cancer is the most frequent malignancy in women in Poland. Overexpression of the HER2 receptor positively correlates with the aggressiveness of the disease. Trastuzumab, a humanized monoclonal antibody against HER2, radically improves the prognosis in such patients. However, its main side effect is cardiotoxicity. The aim of this study is to evaluate the cardiotoxicity in trastuzumab-treated patients. MATERIALS AND METHODS The cases of 19 women treated in the Department of Internal Medicine and Oncologic Chemotherapy Medical University of Silesia in Katowice in the period of 2010–2011 were retrospectively analyzed. RESULTS The median age at the time of diagnosis – 57 years, pathology: invasive ductal carcinoma in 17, invasive lobular carcinoma in 2 patients. Overexpression of HER2 was observed in all the cases. Trastuzumab was administered to 16 of them after previous therapy with antracyclines and/or taxan; the median total antracycline dose was 680 mg. Moreover, 13 patients were subjected to radiotherapy; the median total dose was 50 Gy. In 3 patients, trastuzumab and chemotherapy was used in the management of metastasized disease. The median time between the administration of trastuzumab and anthracyclines was 3 months. The median number of cycles was 10. Before administration of the drug, ECG and echocardiography were performed along with ejection fraction (EF) assessment. Before and after therapy the median EF was 65% and 61%, respectively. The therapy was withheld in 1 patient because of a decrease in EF to 40%. CONCLUSIONS The treatment with trastuzumab was well tolerated. In most patients, we did not observe a significant decrease in EF. However, the cases should be followed up to detect delayed cardiotoxicity.
WSTĘP Rak piersi to najczęstszy nowotwór złośliwy u kobiet w Polsce. W praktyce klinicznej ważne jest określenie ekspresji receptorów, w tym dla naskórkowego czynnika wzrostu typu 2 (HER2) na komórkach nowotworowych. Gdy komórki te wykazują wzmożoną ekspresję HER2, przebieg choroby jest agresywniejszy. Trastuzumab, humanizowane przeciwciało monoklonalne przeciw HER2, znacząco poprawia rokowanie. Jednak terapia taka nie jest pozbawiona działań niepożądanych, w tym kardiotoksyczności. Celem pracy była ocena kardiotoksyczności leczenia trastuzumabem u pacjentek z rakiem piersi. MATERIAŁ I METODY Dokonano retrospektywnej analizy historii chorób 19 kobiet leczonych w Klinice Chorób Wewnętrznych i Chemioterapii Onkologicznej Śląskiego Uniwersytetu Medycznego w Katowicach w latach 2010–2011. WYNIKI Mediana wieku w chwili rozpoznania – 57 lat, typ histologiczny: rak przewodowy naciekający u 17, rak zrazikowy naciekający u 2 pacjentek. Nadekspresję HER2 stwierdzono u wszystkich 19 kobiet, u 16 z nich zastosowano trastuzumab po wcześniejszym leczeniu upełniającym antracyklinami i/lub taksanami – mediana sumarycznej dawki antracyklin 680 mg. U 13 pacjentek dodatkowo przeprowadzono radioterapię – mediana dawki sumarycznej 50 Gy. U 3 pacjentek podano trastuzumab oraz chemioterapię w leczeniu rozsianej choroby nowotworowej. Mediana czasu włączenia trastuzumabu po antracyklinach wyniosła 3 miesiące. Liczba cykli: mediana 10. Przed włączeniem leku wykonano badanie EKG i czynnościowe serca z oceną frakcji wyrzutowej (EF). Mediana EF przed rozpoczęciem leczenia: 65%, po leczeniu: EF 61%. U jednej pacjentki przerwano leczenie z powodu obniżenia EF do 40%. WNIOSKI Leczenie trastuzumabem było dobrze tolerowane. U większości pacjentek nie obserwowano znamiennego obniżenia EF wymagającego odstawienia leku. Badana grupa wymaga jednak badań czynnościowych serca również po odstawienia trastuzumabu w celu wykrycia późnych powikłań kardiotoksycznych.
Źródło:
Annales Academiae Medicae Silesiensis; 2013, 67, 2; 123-127
1734-025X
Pojawia się w:
Annales Academiae Medicae Silesiensis
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 28

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies